Table 1.
Adjuvant therapies in the whole population and according to subtypes.
| Luminal A (N = 386) |
Luminal B N = 408 |
TNBC N = 145 |
All Patients N = 939 |
|
|---|---|---|---|---|
| None | 13 (3.4%) | 13 (3.2%) | 14 (9.6%) | 939 |
| Endocrine therapy alone | 112 (29.0%) | 91 (22.3%) | 0 | 203 (20.7%) |
| CHT + ET | 245 (63.5%) | 279 (68.4%) | 4 1 | 528 (53.9%) |
| CHT regimens | ||||
| Anthracycline-based | 125 (32.4%) | 109 (26.7%) | 32 (22.1%) | 266 (28.3%) |
| Anthracycline + Taxanes | 93 (24.1%) | 137 (33.6%) | 75 (51.7%) | 305 (31.5%) |
| taxanes 2 | 4 (1.0%) | 16 (3.9%) | 7 (4.8%) | 27 (2.9%) |
| CMF | 38 (9.8%) | 40 (9.8%) | 16 (11.0%) | 94 (10.0%) |
| Others | 1 | 2 | 1 | 4 |
1 A total of 4 patients with very low ER and PgR expression (<5%) received ET. 2 taxanes alone or in combination with other drugs are different from anthracyclines.